R&D

Pipeline

Development of Pharmabiotics(LBP)

Indication Indication Discovery Pre-clinical Clinical trial Status
1 2 3
Major Depression Disorder HEMP-001
(Candidate substance H20-01)
US FDA Clinical
2a IND Approved
Autism Spectrum Disorder TBD
Atopic Dermatitis HEMP-001
(Candidate substance H20-01)
Low Anterior Resection
Syndrome		 HEMP-002
(Candidate substance H1036)
AUS HREC Clinical
2a Approved
Cancer-Induced Diarrhea
Chronic Obstructive
Pulmonary Disease		 HEMP-003
(Candidate substance H792)
Non-Alcholic Fatty
Liver Disease		 TBD
Type 2 Diabetes TBD
Constipation (in Children) TBD

Development of
Probiotics

Product name Partner company Contract Product development Trial production Commercialization
BWI Immunity A**
Zeta Bio (B-active) C**
E. Faecium HAC233 L**
MyLAB by NUTRILITE A**
Customized lactic acid bacteria Our company’s new brand